LivaNova PLC Signals Cautious Growth After Strong Quarter

LivaNova PLC ((LIVN)) has held its Q4 earnings call. Read on for the main highlights of the call.

LivaNova’s latest earnings call struck a confident but measured tone, as management highlighted double‑digit growth in core franchises, expanding margins, and a sharply improved balance sheet. At the same time, they acknowledged supply constraints, heavier R&D and capex, and a sizeable assumed legal cash outlay, leading to deliberately conservative near‑term guidance despite strong medium‑term momentum.

Robust Top-Line Growth Across Cardiopulmonary and Epilepsy

LivaNova reported Q4 revenue of $361 million, up 9.5% on a constant currency and organic basis, underscoring healthy demand across its portfolio. Cardiopulmonary was the standout, with full‑year revenue of $785 million rising 13% year over year and Q4 cardiopulmonary sales up 10%, while epilepsy posted 6% full‑year growth and 9% growth in Q4 with broad geographic strength.

Margins and Earnings Tick Higher

Profitability continued to trend upward, with adjusted operating income increasing to $64 million in Q4 from $56 million a year earlier and operating margin improving to 18% from 17%. Adjusted diluted EPS climbed to $0.86 compared with $0.81 in the prior‑year quarter, demonstrating that LivaNova is converting revenue gains into bottom‑line growth even as it steps up investment.

Cash Builds and Leverage Drops

The company exited the year with a cash balance of $636 million, up from $429 million a year earlier, providing a sizable liquidity cushion. Total debt fell sharply to $377 million from $628 million, reflecting early repayments and the settlement of a convertible note, which meaningfully de‑risk the balance sheet.

Free Cash Flow Strength and Outlook Context

Adjusted free cash flow for full‑year 2025 reached $183 million versus $163 million in the prior year, showing solid cash generation despite rising investment. Management framed the 2026 guidance of 6%–7% revenue growth, EPS of $4.15–$4.25, and adjusted free cash flow of $160 million–$180 million within this context, noting that the outlook embeds higher capex and a large assumed legal payment.

Epilepsy Reimbursement Tailwinds and Clinical Validation

The epilepsy franchise gained a powerful tailwind from Medicare, with provider reimbursement for VNS Therapy scheduled to rise by roughly 48% for new implants and 47% for end‑of‑service procedures starting in 2026. Clinically, the 800‑patient CORE VNS study showed compelling and durable outcomes, which management said is reshaping physician perception and reinforcing the case for broader patient access.

Regulatory Wins and Innovation Pipeline Progress

On the innovation front, LivaNova secured FDA approval for its cloud‑based digital health platform that will underpin its Connected Care strategy, enhancing patient monitoring and data integration. In obstructive sleep apnea, the company is nearing the 12‑month OSPREY dataset and remains on track with its modular PMA plan, targeting a clinical trial device approval in the first half and a follow‑on MRI‑compatible supplement.

Essence Adoption and Cardiopulmonary Commercial Levers

Essence, the company’s next‑generation heart‑lung machine, accounted for about 55% of annual placements in 2025, with a goal to reach around 80% penetration by 2026, supporting ongoing mix and pricing benefits. Cardiopulmonary consumables grew in the mid‑teens in Q4 and low‑teens for the year, driven by market‑share gains, procedure growth, and favorable pricing dynamics.

Strategic Capex and Future Product Launches

Management emphasized continued investment in future growth drivers, noting that design freeze has been completed for the next‑generation oxygenator and the team is now moving into scale‑up ahead of a planned 2028 launch. In neuromodulation, LivaNova plans a limited rollout of a clinician portal in 2026 and a full commercial launch of a digital and Bluetooth‑enabled epilepsy generator in 2027, positioning the franchise for a more connected ecosystem.

Supply Constraints and Manufacturing Expansion

Oxygenator demand exceeded available supply in 2025, highlighting the strength of the cardiopulmonary business but also exposing operational bottlenecks. Due to third‑party component constraints, the company adopted conservative assumptions for 2026 oxygenator output and is investing in capacity expansions and deeper supplier partnerships to better align supply with demand.

Timing Shifts Weigh on Q4 but Not Demand

Some expected Essence heart‑lung machine placements and related tender activity slipped from Q4 into early 2026, tempering the quarter’s reported contribution but not underlying interest in the platform. Management expects to recapture most of these delayed orders in Q1 2026, suggesting the impact is primarily timing rather than demand erosion.

Higher R&D and Capex Temporarily Pressure Cash and Margins

Adjusted R&D spending rose to $49 million in Q4, or 14% of revenue, from $40 million and 13% a year earlier, as the company ramps programs in OSA and core product development. This heavier investment, coupled with higher capital spending, contributed to a year‑over‑year decline in Q4 adjusted free cash flow to $53 million from $62 million, though management frames this as a deliberate choice to support future launches.

Large Assumed SNIA Payment Embedded in Cash Outlook

Guidance incorporates an estimated $400 million SNIA‑related payment in the third quarter of 2026, a sizeable cash use that management has explicitly factored into its planning. This assumption leads to an estimated $0.06 unfavorable impact on adjusted free cash flow and is directly reflected in the 2026 FCF guidance range, signaling a conservative stance on legal and settlement risk.

Tax and FX Headwinds Offset Some Margin Gains

The adjusted effective tax rate increased to 24% in Q4 from 20% a year earlier, driven by geographic mix shifts and the expiration of certain tax benefits, providing a modest headwind to net earnings. Currency movements and tariffs also partially offset operating improvements, leaving the adjusted gross margin at 68%, essentially flat with the prior year despite underlying efficiency gains.

Moderated Guidance After a Stretch of Double-Digit Growth

After several years of double‑digit organic revenue and EPS growth, management guided to 6%–7% constant‑currency revenue growth in 2026, a clear step‑down in pace. Executives attributed this moderation to tough comparisons and conservative assumptions, including a reduced price premium on Essence and cautious expectations for oxygenator output, rather than any deterioration in demand fundamentals.

Uncertain CMS Timing for Depression Expansion

LivaNova continues to work with regulators on reimbursement reconsideration for difficult‑to‑treat depression, which could open a sizable new neuromodulation market if successful. However, management emphasized that the timing and outcome of the process remain uncertain, and thus they are not embedding material contributions from this opportunity into the near‑term guidance.

Epilepsy Mix Limits Visibility of New-Patient Growth

Roughly two‑thirds of U.S. epilepsy revenue comes from replacement implants, creating a stable and recurring revenue stream but diluting the visible impact of new‑patient starts on top‑line growth. As a result, even solid increases in new implant volumes may translate into only modest near‑term epilepsy revenue acceleration, though they build a larger installed base for future replacements.

Guidance Emphasizes Steady Growth and Balance-Sheet Strength

For 2026, LivaNova projects 6%–7% constant‑currency revenue growth, with cardiopulmonary expected to rise 7%–8% and epilepsy 5.5%–6.5%, while adjusted diluted EPS is forecast at $4.15–$4.25, about 8% growth at the midpoint. The company expects $160 million–$180 million in adjusted free cash flow after roughly $120 million in capital spending and the planned SNIA payment, underpinned by a strong cash position, lower debt, and ongoing investments in Essence penetration, OSA, and Connected Care.

LivaNova’s earnings call painted the picture of a company balancing near‑term caution with clear long‑term ambition, as solid growth, improving margins, and a strengthened balance sheet underpin continued investment in high‑potential platforms. For investors, the moderated guidance, supply constraints, and legal cash assumptions may temper expectations in the short run, but the commercial momentum and innovation pipeline suggest an attractive medium‑term growth story.